Syncor wins clearance for palladium seeds

February 16, 2000

Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills,

Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills, CA-based Syncor’s iodine-125 seeds, also for prostate cancer (SCAN 2/2/00). The company plans to market the two products under the trade name PharmaSeed.

In other Syncor news, the firm announced the resignation of Brad Nutter, executive vice president and COO. Nutter left Syncor on Feb. 11 for the position of president of Gambro Healthcare. While Syncor seeks a permanent replacement for Nutter, its pharmacy services executive team will report to president and CEO Robert Funari.